Carboplatin/Paclitaxel
Phase 3Small molecule
AstraZenecaCarboplatin/Paclitaxel is one of 142 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.
5
Indications
9
Total Trials
4
Active Trials
141
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Carboplatin/Paclitaxel
AstraZenecaPhase 3
Yervoy
Bristol-Myers SquibbPreclinical
PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Carboplatin1 trial
Esophageal Cancer1 trial
Ovarian Cancer1 trial
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
Completed·—·Phase 1/2·NCT05963334·49 enrolled
2 more indications
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carboplatin/Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company